These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Is prasugrel more effective than clopidogrel in patients with acute coronary syndrome scheduled for PCI? Graber MA; Dachs R; Darby-Stewart A Am Fam Physician; 2008 Dec; 78(11):1252-3. PubMed ID: 19069017 [No Abstract] [Full Text] [Related]
3. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956 [TBL] [Abstract][Full Text] [Related]
5. [Interview with Prof. Franz-Joseph Krozingen: Interventional cardiology on the success course]. Neumann FJ MMW Fortschr Med; 2010 Apr; 152(13):18. PubMed ID: 20443337 [No Abstract] [Full Text] [Related]
6. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. Mariani M; Mariani G; De Servi S Expert Rev Cardiovasc Ther; 2009 Jan; 7(1):17-23. PubMed ID: 19105763 [TBL] [Abstract][Full Text] [Related]
8. [Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?]. Silber S; Helms TM; Garlichs C; Arntz HR; Weil J; Ince H; Klingenheben T; Hoffmann S; Boudriot E; Steiger H; Zugck C Dtsch Med Wochenschr; 2011 Apr; 136(15):782-5. PubMed ID: 21432747 [No Abstract] [Full Text] [Related]
9. [Prodrug activation as a crucial difference. Prasugrel - a new ADP receptor antagonist]. Alban S Pharm Unserer Zeit; 2009; 38(4):320-8. PubMed ID: 19572350 [No Abstract] [Full Text] [Related]
10. [Pharmazie in unserer Zeit 4/2009]. Alban S; Dingermann T Pharm Unserer Zeit; 2009; 38(4):295. PubMed ID: 19572344 [No Abstract] [Full Text] [Related]
11. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes. Toth PP Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814 [TBL] [Abstract][Full Text] [Related]
16. Intensifying platelet inhibition--navigating between Scylla and Charybdis. Bhatt DL N Engl J Med; 2007 Nov; 357(20):2078-81. PubMed ID: 17982183 [No Abstract] [Full Text] [Related]
17. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245 [TBL] [Abstract][Full Text] [Related]
18. Platelet P2 receptors: old and new targets for antithrombotic drugs. Cattaneo M Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):45-55. PubMed ID: 17187456 [TBL] [Abstract][Full Text] [Related]
19. Prasugrel: a critical comparison with clopidogrel. Reinhart KM; White CM; Baker WL Pharmacotherapy; 2009 Dec; 29(12):1441-51. PubMed ID: 19947804 [TBL] [Abstract][Full Text] [Related]